Articles By Jack Cush, MD
Hot Stuff Part III: Zoster and Biologics: Special Considerations
Part III covers talks on H. Zoster, biologics and SpA.
Read Article
Medical Marijuana for Osteoarthritis in Illinois
An advisory board has recommended osteoarthritis and a host of disorders for inclusion in the Illinois new medical marijuana program.
Read Article
Most Prescribed Branded Drugs Through March 2015
In the last 12 months, levothyroxine (Synthroid) was the most prescribed drug in the USA with 21.6 million prescriptions. Adalimumab (Humira) had 8.3 billion in sales, followed by etanercept (Enbrel) at nearly $6 billion.
Read Article
Who Should Pay for Drug 'Take-Back' Programs
Unused pills and prescriptions pose a significant safety risk in the home and may contribute to dosing errors or inadvertent drug use. The issue has led the DEA to sponsor national drug disposal programs and local municipalities have followed with similar programs. At issue is who shoul
Read Article
FDA Outlines its Guidance for Biosimilars
The FDA has released its guidance document on biosimilar development, stating that this represents its current thinking and may not be the final document. The document was published last week and will be instrumental in the development of biosimilar products in this country. In the
Read Article
Time for a New War on Drugs (Their Prices, That Is)
Biologics are not only expensive, their costs have continued to rise. This is not only true for rheumatology, as other specialties have unique biopharmaceuticals that have changed prescribing paradigms. Jim Davis of AdverseEvents.com wri
Read Article
Adjuvant Herpes Zoster Subunit Vaccine is 97% Effective in Adults
The hazards of live virus vaccines are familiar to those who manage immunosuppression in the setting of inflammatory or autoimmune disease. One in three adults will contract "shingles" (VZV) infection in their lifetime. Given the pain and mobidity associated with this infection, the
Read Article
Drug-Induced Lupus is Rare with TNF inhibitor Therapy
Drug-induced lupus (DIL) has been associated with all TNF inhibitors. Early rates suggested this may be between 0.04 - 0.06 events per 100 patient-years or roughtly 5 per 1000 patient-years.
Read Article
Real World Biologic Success in Systemic JIA
A retrospective review of 77 SoJIA patients revealed that 50-70% achieved inactive disease or remission when treated with IL-1 inhibitors (anakinra, canakinumab). Good responses were seen with tocilizumab or abatacept, but only 8% responded to etanercept.
Read Article
Hot Stuff Part II: Current Status and Recommendations on Vaccines and Biologics
Part II highlights from the Cleveland Clinic's Biologic Therapies Summit.
Read Article
